Although amylin was discovered decades ago, its importance in everyday clinical practice has long been underestimated. New pharmacological developments are increasingly bringing amylin into the focus of diabetes and obesity therapy, and amylin analogs, some of which have already passed phase 3 clinical trials, are now among the most promising approaches in overweight and obesity pharmacotherapy.
Autoren
- Dr. Stephanie Niklaus
- Prof. Dr. med. vet. Thomas A. Lutz
Publikation
- InFo DIABETOLOGIE & ENDOKRINOLOGIE
Related Topics
You May Also Like
- Type 2 diabetes: sarcopenia and frailty
How can the breakdown of skeletal muscles be stopped?
- Cholangiocarcinoma
Modern molecular diagnostics and targeted therapy options
- Treatment resistant depression
Esketamine nasal spray as monotherapy? New for treatment-resistant depression
- Analysis of SNVCS data from the period 2005-2022
TBE vaccination for children and adolescents in Switzerland
- Tuberculosis
Detecting diabetes in TB patients early and efficiently
- Trichophyton indotineae
Terbinafine-resistant dermatophytoses are on the rise in Central Europe
- Peristomal skin health
Focus on preventive care options
- Disease-modifying therapies for ATTR-CM